|
1
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar
|
|
2
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar
|
|
3
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar
|
|
4
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar
|
|
5
|
McCabe N, Turner NC, Lord CJ, Kluzek K,
Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka
MZ, et al: Deficiency in the repair of DNA damage by homologous
recombination and sensitivity to poly(ADP-ribose) polymerase
inhibition. Cancer Res. 66:8109–8115. 2006. View Article : Google Scholar
|
|
6
|
Kim G, Ison G, McKee AE, Zhang H, Tang S,
Gwise T, Sridhara R, Lee E, Tzou A, Philip R, et al: FDA approval
summary: Olaparib monotherapy in patients with deleterious germline
BRCA-mutated advanced ovarian cancer treated with three or more
lines of chemotherapy. Clin Cancer Res. 21:4257–4261. 2015.
View Article : Google Scholar
|
|
7
|
Lord CJ and Ashworth A: BRCAness
revisited. Nat Rev Cancer. 16:110–120. 2016. View Article : Google Scholar
|
|
8
|
Ashworth A and Lord CJ: Synthetic lethal
therapies for cancer: What's next after PARP inhibitors? Nat Rev
Clin Oncol. 15:564–576. 2018. View Article : Google Scholar
|
|
9
|
Litton JK, Rugo HS, Ettl J, Hurvitz SA,
Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin
M, et al: Talazoparib in patients with advanced breast cancer and a
germline BRCA mutation. N Engl J Med. 379:753–763. 2018. View Article : Google Scholar
|
|
10
|
Smeby J, Kryeziu K, Berg KCG, Eilertsen
IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe
RA and Sveen A: Molecular correlates of sensitivity to PARP
inhibition beyond homologous recombination deficiency in
pre-clinical models of colorectal cancer point to wild-type TP53
activity. EBioMedicine. 59:1029232020. View Article : Google Scholar
|
|
11
|
Audeh MW, Carmichael J, Penson RT,
Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN,
Oaknin A, Loman N, et al: Oral poly(ADP-ribose) polymerase
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and
recurrent ovarian cancer: A proof-of-concept trial. Lancet.
376:245–251. 2010. View Article : Google Scholar
|
|
12
|
Fong PC, Yap TA, Boss DS, Carden CP,
Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S,
Messiou C, et al: Poly(ADP)-ribose polymerase inhibition: Frequent
durable responses in BRCA carrier ovarian cancer correlating with
platinum-free interval. J Clin Oncol. 28:2512–2519. 2010.
View Article : Google Scholar
|
|
13
|
Gelmon KA, Tischkowitz M, Mackay H,
Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M,
Gilks B, et al: Olaparib in patients with recurrent high-grade
serous or poorly differentiated ovarian carcinoma or
triple-negative breast cancer: A phase 2, multicentre, open-label,
non-randomised study. Lancet Oncol. 12:852–861. 2011. View Article : Google Scholar
|
|
14
|
Jiang X, Li X, Li W, Bai H and Zhang Z:
PARP inhibitors in ovarian cancer: Sensitivity prediction and
resistance mechanisms. J Cell Mol Med. 23:2303–2313. 2019.
View Article : Google Scholar
|
|
15
|
Noordermeer SM and van Attikum H: PARP
inhibitor resistance: A tug-of-war in BRCA-mutated cells. Trends
Cell Biol. 29:820–834. 2019. View Article : Google Scholar
|
|
16
|
Lee EK and Matulonis UA: PARP inhibitor
resistance mechanisms and implications for post-progression
combination therapies. Cancers (Basel). 12:20542020. View Article : Google Scholar
|
|
17
|
Dias MP, Moser SC, Ganesan S and Jonkers
J: Understanding and overcoming resistance to PARP inhibitors in
cancer therapy. Nat Rev Clin Oncol. 18:773–791. 2021. View Article : Google Scholar
|
|
18
|
Lin KK, Harrell MI, Oza AM, Oaknin A,
Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, et al:
BRCA reversion mutations in circulating tumor DNA predict primary
and acquired resistance to the PARP inhibitor rucaparib in
high-grade ovarian carcinoma. Cancer Discov. 9:210–219. 2019.
View Article : Google Scholar
|
|
19
|
Mayor P, Gay LM, Gornstein E, Morley S,
Frampton GM, Heilmann A, Sun J, Chung J, Daniel S, Ramkissoon S, et
al: BRCA1/2 reversion mutations revealed in breast and gynecologic
cancers sequenced during routine clinical care using tissue or
liquid biopsy. J Clin Oncol. 35:55512017. View Article : Google Scholar
|
|
20
|
Kondrashova O, Nguyen M, Shield-Artin K,
Tinker AV, Teng NN, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin
M, et al: Secondary somatic mutations restoring RAD51C and RAD51D
associated with acquired resistance to the PARP inhibitor rucaparib
in high-grade ovarian carcinoma. Cancer Discov. 7:984–998. 2017.
View Article : Google Scholar
|
|
21
|
Brugge PT, Kristel P, Van Der Burg E, Boon
U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C,
Gevensleben H, et al: Mechanisms of therapy resistance in
patient-derived xenograft models of BRCA1-deficient breast cancer.
J Natl Cancer Inst. 108: View Article : Google Scholar : 2016.
|
|
22
|
Kondrashova O, Topp M, Nesic K, Lieschke
E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, et
al: Methylation of all BRCA1 copies predicts response to the PARP
inhibitor rucaparib in ovarian carcinoma. Nat Commun. 9:39702018.
View Article : Google Scholar
|
|
23
|
Bunting SF, Callén E, Wong N, Chen HT,
Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao
L, et al: 53BP1 inhibits homologous recombination in
Brca1-deficient cells by blocking resection of DNA breaks. Cell.
141:243–254. 2010. View Article : Google Scholar
|
|
24
|
Xu G, Chapman JR, Brandsma I, Yuan J,
Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M,
et al: REV7 counteracts DNA double-strand break resection and
affects PARP inhibition. Nature. 521:541–544. 2015. View Article : Google Scholar
|
|
25
|
Pettitt SJ, Krastev DB, Brandsma I, Dréan
A, Song F, Aleksandrov R, Harrell M, Menon M, Brough, Campbell J,
et al: Genome-wide and high-density CRISPR-Cas9 screens identify
point mutations in PARP1 causing PARP inhibitor resistance. Nat
Commun. 9:18492018. View Article : Google Scholar
|
|
26
|
Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL,
Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR IV, et al: Blocking
c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of
PARP inhibitors. Nat Med. 22:194–201. 2016. View Article : Google Scholar
|
|
27
|
Chaudhuri AR, Callen E, Ding X, Gogola E,
Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, et
al: Replication fork stability confers chemoresistance in
BRCA-deficient cells. Nature. 535:382–387. 2016. View Article : Google Scholar
|
|
28
|
Taglialatela A, Alvarez S, Leuzzi G,
Sannino V, Ranjha L, Huang JW, Madubata C, Anand R, Levy B, Rabadan
R, et al: Restoration of replication fork stability in BRCA1- and
BRCA2-deficient cells by inactivation of SNF2-family fork
remodelers. Mol Cell. 68:414–430. 2017. View Article : Google Scholar
|
|
29
|
Rottenberg S, Jaspers JE, Kersbergen A,
van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M,
Zevenhoven J, Lau A, et al: High sensitivity of BRCA1-deficient
mammary tumors to the PARP inhibitor AZD2281 alone and in
combination with platinum drugs. Proc Natl Acad Sci USA.
105:17079–17084. 2008. View Article : Google Scholar
|
|
30
|
Christie EL, Fereday S, Doig K, Pattnaik
S, Dawson SJ and Bowtell DDL: Reversion of BRCA1/2 germline
mutations detected in circulating tumor DNA from patients with
high-grade serous ovarian cancer. J Clin Oncol. 35:1274–1280. 2017.
View Article : Google Scholar
|
|
31
|
Yamamoto TM, McMellen A, Watson ZL,
Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim
H, Cittelly DM, et al: Activation of Wnt signaling promotes
olaparib resistant ovarian cancer. Mol Carcinog. 58:1770–1782.
2019. View Article : Google Scholar
|
|
32
|
Nesic K, Kondrashova O, Hurley RM, McGehee
CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin
K, et al: Acquired RAD51C promoter methylation loss causes PARP
inhibitor resistance in high grade serous ovarian carcinoma. Cancer
Res. 81:4709–4722. 2021. View Article : Google Scholar
|
|
33
|
Póti Á, Berta K, Xiao Y, Pipek O, Klus GT,
Ried T, Csabai I, Wilcoxen K, Mikule K, Szallasi Z and Szüts D:
Long-term treatment with the PARP inhibitor niraparib does not
increase the mutation load in cell line models and tumour
xenografts. Br J Cancer. 119:1392–1400. 2018. View Article : Google Scholar
|
|
34
|
Domcke S, Sinha R, Levine DA, Sander C and
Schultz N: Evaluating cell lines as tumour models by comparison of
genomic profiles. Nat Commun. 4:21262013. View Article : Google Scholar
|
|
35
|
Behrens BC, Hamilton TC, Masuda H,
Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young
RC and Ozols RF: Characterization of a cis-diamminedichloroplat
inum(II)-resistant human ovarian cancer cell line and its use in
evaluation of platinum analogues. Cancer Res. 47:414–148. 1987.
|
|
36
|
Yoshiya N, Adachi S, Misawa Y, Yuzawa H,
Honda T, Kanazawa K, Takeuchi S and Tanaka K and Tanaka K:
Isolation of cisplatin-resistant subline from human ovarian cancer
cell line and analysis of its cell-biological characteristics.
Nihon Sanka Fujinka Gakkai Zasshi. 41:7–14. 1989.In Japanese.
|
|
37
|
Montavon C, Stricker GR, Schoetzau A,
Heinzelmann-Schwarz V, Jacob F and Fedier A: Outcome in serous
ovarian cancer is not associated with LATS expression. J Cancer Res
Clin Oncol. 145:2737–2749. 2019. View Article : Google Scholar
|
|
38
|
Fedier A, Dedes KJ, Imesch P, Von Bueren
AO and Fink D: The histone deacetylase inhibitors suberoylanilide
hydroxamic (Vorinostat) and valproic acid induce irreversible and
MDR1-independent resistance in human colon cancer cells. Int J
Oncol. 31:633–741. 2007.
|
|
39
|
Dedes KJ, Dedes I, Imesch P, von Bueren
AO, Fink D and Fedier A: Acquired vorinostat resistance shows
partial cross-resistance to 'second-generation' HDAC inhibitors and
correlates with loss of histone acetylation and apoptosis but not
with altered HDAC and HAT activities. Anticancer Drugs. 20:321–333.
2009. View Article : Google Scholar
|
|
40
|
Imesch P, Dedes KJ, Furlato M, Fink D and
Fedier A: MLH1 protects from resistance acquisition by the histone
deacetylase inhibitor trichostatin A in colon tumor cells. Int J
Oncol. 35:631–640. 2009.
|
|
41
|
Shin S, Kim SH, Shin SW, Grav LM, Pedersen
LE, Lee JS and Lee GM: Comprehensive analysis of genomic safe
harbors as target sites for stable expression of the heterologous
gene in HEK293 cells. ACS Synth Biol. 9:1263–1269. 2020. View Article : Google Scholar
|
|
42
|
Brinkman EK, Chen T, Amendola M and van
Steensel B: Easy quantitative assessment of genome editing by
sequence trace decomposition. Nucleic Acids Res. 42:e1682014.
View Article : Google Scholar
|
|
43
|
Kohler RS, Kettelhack H,
Knipprath-Mészaros AM, Fedier A, Schoetzau A, Jacob F and
Heinzelmann-Schwarz V: MELK expression in ovarian cancer correlates
with poor outcome and its inhibition by OTSSP167 abrogates
proliferation and viability of ovarian cancer cells. Gynecol Oncol.
145:159–166. 2017. View Article : Google Scholar
|
|
44
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar
|
|
45
|
Lapinska K, Housman G, Byler S, Heerboth
S, Willbanks A, Oza A and Sarkar S: The effects of histone
deacetylase inhibitor and calpain inhibitor combination therapies
on ovarian cancer cells. Anticancer Res. 36:5731–7542. 2016.
View Article : Google Scholar
|
|
46
|
Matulonis U, Berlin S, Lee H, Whalen C,
Obermayer E, Penson R, Liu J, Campos S, Krasner C and Horowitz N:
Phase I study of combination of vorinostat, carboplatin, and
gemcitabine in women with recurrent, platinum-sensitive epithelial
ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother
Pharmacol. 76:417–423. 2015. View Article : Google Scholar
|
|
47
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA and
Gynecologic Oncology Group: Gynecologic oncology group:
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl
J Med. 354:34–43. 2006. View Article : Google Scholar
|
|
48
|
Pennington KP, Walsh T, Harrell MI, Lee
MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord
AS, et al: Germline and somatic mutations in homologous
recombination genes predict platinum response and survival in
ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer
Res. 20:764–775. 2014. View Article : Google Scholar
|
|
49
|
Nitiss JL: Targeting DNA topoisomerase II
in cancer chemotherapy. Nat Rev Cancer. 9:338–350. 2009. View Article : Google Scholar
|
|
50
|
Adams SF, Marsh EB, Elmasri W, Halberstadt
S, Vandecker S, Sammel MD, Bradbury AR, Daly M, Karlan B and Rubin
SC: A high response rate to liposomal doxorubicin is seen among
women with BRCA mutations treated for recurrent epithelial ovarian
cancer. Gynecol Oncol. 123:486–491. 2011. View Article : Google Scholar
|
|
51
|
Zaremba T, Thomas H, Cole M, Plummer ER
and Curtin NJ: Doxorubicin-induced suppression of poly(ADP-ribose)
polymerase-1 (PARP-1) activity and expression and its implication
for PARP inhibitors in clinical trials. Cancer Chemother Pharmacol.
66:807–812. 2010. View Article : Google Scholar
|
|
52
|
Robert C and Rassool FV: HDAC inhibitors:
Roles of DNA damage and repair. Adv Cancer Res. 116:87–129. 2012.
View Article : Google Scholar
|
|
53
|
Ha K, Fiskus W, Choi DS, Bhaskara S,
Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM,
et al: Histone deacetylase inhibitor treatment induces 'BRCAness'
and synergistic lethality with PARP inhibitor and cisplatin against
human triple negative breast cancer cells. Oncotarget. 5:5637–5650.
2014. View Article : Google Scholar
|
|
54
|
Weaver BA: How taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar
|
|
55
|
Slade D: Mitotic functions of
poly(ADP-ribose) polymerases. Biochem Pharmacol. 167:33–43. 2019.
View Article : Google Scholar
|
|
56
|
McCormick A and Swaisland H: In vitro
assessment of the roles of drug transporters in the disposition and
drug-drug interaction potential of olaparib. Xenobiotica.
47:903–915. 2017. View Article : Google Scholar
|
|
57
|
Wheeler DA, Takebe N, Hinoue T, Hoadley
KA, Cardenas MF, Hamilton AM, Laird PW, Wang L, Johnson A, Dewal N,
et al: Molecular features of cancers exhibiting exceptional
responses to treatment. Cancer Cell. 39:38–53. 2021. View Article : Google Scholar
|
|
58
|
Sanderson BJ, Ferguson LR and Denny WA:
Mutagenic and carcinogenic properties of platinum-based anticancer
drugs. Mutat Res. 355:59–70. 1996. View Article : Google Scholar
|
